Magnetic resonance elastography plus Fibrosis‐4 versus FibroScan–aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH‐related fibrosis
Abstract
Patients with NAFLD with significant hepatic fibrosis (Stage ≥ 2) are at increased risk of liver‐related morbidity and are candidates for pharmacologic therapies. In this study, we compared the diagnostic accuracy of MEFIB (the combination of magnetic resonance elastography [MRE] and Fibrosis‐4 [FIB‐4]) and FAST (FibroScan–aspartate aminotransferase; combined liver stiffness measurement by vibration‐controlled transient elastography, controlled attenuation parameter, and aspartate aminotransferase) for detecting significant fibrosis.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 15, 2021
- Source ID
- 10.1002/hep.32145
Entities
People
- Atsushi Nakajima
- Claude B. Sirlin
- Cynthia Behling
- Jinho Jung
- Kento Imajo
- Mark A. Valasek
- Masato Yoneda
- Nobuharu Tamaki
- Nobuyoshi Kawamura
- Rohit Loomba
- Suzanne Sharpton
Organizations
- University of California, San Diego
- Yokohama City University